Formycon AG (XETRA:FYB) — Market Cap & Net Worth
Market Cap & Net Worth: Formycon AG (FYB)
Formycon AG (XETRA:FYB) has a market capitalization of $336.85 Million (€288.12 Million) as of June 18, 2026. Listed on the XETRA stock exchange, this Germany-based company holds position #14391 globally and #1440 in its home market, demonstrating a -0.60% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Formycon AG's stock price €19.98 by its total outstanding shares 17672927 (17.67 Million). Review Formycon AG total liabilities to assess the company's total debt and financial obligations.
Formycon AG Market Cap History: 2015 to 2026
Formycon AG's market capitalization history from 2015 to 2026. Data shows change from $491.02 Million to $412.82 Million (-1.39% CAGR).
Index Memberships
Formycon AG is a constituent of 1 market index:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
HDAX Price
GDAXHIP
|
$1.24 Trillion | 0.03% | #63 of 102 |
Weight: Formycon AG's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Formycon AG Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Formycon AG's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
11.89x
Formycon AG's market cap is 11.89 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $493.60 Million | $19.53 Million | -$4.07 Million | 25.27x | N/A |
| 2017 | $675.53 Million | $29.00 Million | -$1.58 Million | 23.29x | N/A |
| 2018 | $537.20 Million | $42.99 Million | $7.10 Million | 12.49x | 75.68x |
| 2019 | $659.10 Million | $33.16 Million | -$2.29 Million | 19.88x | N/A |
| 2020 | $1.10 Billion | $34.23 Million | -$6.73 Million | 31.99x | N/A |
| 2021 | $1.22 Billion | $36.61 Million | -$13.29 Million | 33.29x | N/A |
| 2022 | $1.79 Billion | $42.50 Million | $35.99 Million | 42.06x | 49.66x |
| 2023 | $1.17 Billion | $77.70 Million | $75.80 Million | 15.00x | 15.37x |
| 2024 | $1.10 Billion | $69.67 Million | -$125.67 Million | 15.75x | N/A |
| 2025 | $528.93 Million | $44.48 Million | -$64.70 Million | 11.89x | N/A |
Competitor Companies of FYB by Market Capitalization
Companies near Formycon AG in the global market cap rankings as of June 18, 2026.
Key companies related to Formycon AG by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #222 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #442 globally with a market cap of $63.33 Billion USD.
- UCB SA (BR:UCB): Ranked #550 globally with a market cap of $49.68 Billion USD ( €42.50 Billion EUR).
- Argen-X (BR:ARGX): Ranked #574 globally with a market cap of $47.14 Billion USD ( €40.32 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #222 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $453.17 |
| #442 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $63.33 Billion | $614.73 |
| #550 | UCB SA | BR:UCB | $49.68 Billion | €250.00 |
| #574 | Argen-X | BR:ARGX | $47.14 Billion | €755.80 |
Formycon AG Historical Marketcap From 2015 to 2026
Between 2015 and today, Formycon AG's market cap moved from $491.02 Million to $ 412.82 Million, with a yearly change of -1.39%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €412.82 Million | -21.95% |
| 2025 | €528.93 Million | -51.79% |
| 2024 | €1.10 Billion | -5.85% |
| 2023 | €1.17 Billion | -34.80% |
| 2022 | €1.79 Billion | +46.61% |
| 2021 | €1.22 Billion | +11.32% |
| 2020 | €1.10 Billion | +66.14% |
| 2019 | €659.10 Million | +22.69% |
| 2018 | €537.20 Million | -20.48% |
| 2017 | €675.53 Million | +36.86% |
| 2016 | €493.60 Million | +0.53% |
| 2015 | €491.02 Million | -- |
End of Day Market Cap According to Different Sources
On Jun 17th, 2026 the market cap of Formycon AG was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $336.85 Million USD |
| MoneyControl | $336.85 Million USD |
| MarketWatch | $336.85 Million USD |
| marketcap.company | $336.85 Million USD |
| Reuters | $336.85 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Formycon AG
Formycon AG, a biotechnology company, develops biosimilar drugs in Germany and Switzerland. It provides ranibizumab and aflibercept used in the treatment of neovascular age-related macular degeneration, diabetic macular edema, choroidal neovascularization, proliferative diabetic retinopathy, and macular edema under the Ranivisio, Ongavia, Cimerli, Ranopto, Uptera, and Ravegza brand names, as well… Read more